What are the appropriate indications, dosing, contraindications, monitoring, and counseling points for finasteride in men?

Finasteride for Men: Clinical Guide

Finasteride 5 mg daily is indicated for symptomatic benign prostatic hyperplasia (BPH) in men with enlarged prostates (>30cc or PSA >1.5 ng/mL) to improve symptoms, reduce acute urinary retention risk, and decrease need for surgery; finasteride 1 mg daily is used for androgenetic alopecia, though this lower dose also reduces PSA by approximately 40-50%. 1, 2, 3

Indications

BPH (5 mg daily)

• Monotherapy: Symptomatic BPH with enlarged prostate to improve symptoms, reduce acute urinary retention risk, and reduce surgical need including TURP 1
• Combination therapy: With alpha-blockers (e.g., doxazosin) to reduce symptomatic BPH progression (≥4 point AUA symptom score increase) 1
• Optimal candidates: Prostate volume >30cc or PSA >1.5 ng/mL—larger glands show more pronounced effects 2
• Mechanism: Reduces prostate volume by 15-25% at 6 months through selective type II 5α-reductase inhibition, decreasing DHT by ~70% in serum and ~80% in prostate tissue 2, 4

Androgenetic Alopecia (1 mg daily)

• Male pattern hair loss in men aged 18-60 years 5, 6
• Increases total hair count significantly: 12.4 hairs/cm² at 24 weeks and 16.4 hairs/cm² at 48 weeks versus placebo 5

Dosing

BPH

• Standard dose: 5 mg orally once daily 1
• Onset of action: Slow compared to alpha-blockers; counsel patients on delayed symptom improvement (3-4 point IPSS improvement over 6-10 years) 2
• Duration: Long-term therapy required; effects reverse upon discontinuation 4

Androgenetic Alopecia

• Standard dose: 1 mg orally once daily 5, 6
• Dose-ranging: 0.2-5 mg/day shows efficacy, but 1 mg is optimal (similar efficacy to 5 mg with better tolerability) 7

Pharmacokinetics

• Well absorbed orally; food slows absorption rate but doesn't affect total bioavailability 4
• Terminal half-life: 4.7-7.1 hours, but DHT suppression lasts up to 4 days due to high enzyme affinity 4
• Hepatic metabolism to inactive metabolites; no renal dose adjustment needed 4

Contraindications & Precautions

Absolute Contraindications

• Women of childbearing potential (teratogenic to male fetuses) 1
• Pregnancy 1
• Hypersensitivity to finasteride 1

Important Warnings

• High-grade prostate cancer risk: Increased incidence of Gleason 8-10 prostate cancer (1.8% vs 1.1% placebo in PCPT trial); not approved for prostate cancer prevention 1
• Breast cancer: Rare cases reported in men on finasteride; relationship unclear but documented in post-marketing surveillance 1
• Surgical considerations: Reduces intraoperative bleeding and transfusion need during TURP 2

Monitoring

PSA Monitoring (Critical)

• BPH patients (5 mg): PSA decreases by ~50% after 1 year; double the measured PSA value to accurately gauge prostate cancer risk 2
• Androgenetic alopecia patients (1 mg): PSA decreases by 40% (age 40-49) to 50% (age 50-60) within 48 weeks; apply same doubling adjustment for cancer screening 3
• Free/total PSA ratio: Remains constant despite absolute reductions 2
• Counsel patients on PSA alterations before initiating therapy 2

Baseline Assessment

• Prostate volume assessment via TRUS or cross-sectional imaging for BPH patients (reserve for glands >30cc) 2
• Baseline PSA before treatment initiation 2
• Digital rectal examination 1

Ongoing Monitoring

• Annual PSA and digital rectal exams for prostate cancer screening 1
• Symptom assessment (AUA-SI/IPSS scores) 2
• Sexual function assessment 1

Adverse Effects & Counseling

Sexual Dysfunction (Most Common)

BPH (5 mg) - 4-year data: 1

• Impotence: 8.1% (year 1) vs 3.7% placebo; equalizes to 5.1% both groups in years 2-4
• Decreased libido: 6.4% (year 1) vs 3.4% placebo; equalizes to 2.6% both groups in years 2-4
• Decreased ejaculate volume: 3.7% vs 0.8% placebo (year 1)
• Ejaculation disorder: 0.8% vs 0.1% placebo (year 1)

Combination therapy with doxazosin: 1

• Impotence: 22.6% (combination) vs 18.5% (finasteride alone) vs 14.4% (doxazosin alone)
• Decreased libido: 11.6% vs 10.0% vs 7.0%
• Abnormal ejaculation: 14.1% vs 7.2% vs 4.5%

Post-Finasteride Syndrome (PFS)

• Controversial entity: Poorly-defined constellation of sexual, physical, and psychological symptoms that putatively persist after discontinuation 2
• FDA amended labels in 2011 with warning based on anecdotal patient reports, not prospective trials 2
• Depression added to FDA label in 2011; suicide risk concerns related to persistent sexual effects 5
• Evidence quality: Based on patient-reported outcomes rather than robust clinical trial data 2
• Recent disproportionality analysis suggests nocebo effect may contribute to reporting patterns, especially post-2012 when PFS awareness increased 8

Other Adverse Effects

• Gynecomastia: 0.5% (year 1), 1.8% (years 2-4) vs 0.1-1.1% placebo 1
• Breast tenderness: 0.4% (year 1), 0.7% (years 2-4) 1
• Hypersensitivity: Pruritus, urticaria, angioedema (rare, post-marketing) 1
• Male infertility: Rare reports of poor seminal quality; normalization reported after discontinuation 1
• Hematospermia: Rare post-marketing report 1

Key Counseling Points

1. Sexual side effects: Most common in first year, typically resolve with continued therapy; inform about potential for persistent dysfunction (rare) 1, 2
2. Slow onset: For BPH, symptom improvement takes months (unlike alpha-blockers); set realistic expectations 2
3. PSA effects: Must inform all healthcare providers about finasteride use for accurate prostate cancer screening 2, 3
4. Pregnancy risk: Male partners should not donate blood during treatment and for 1 month after; pregnant women should not handle crushed/broken tablets 1
5. Long-term commitment: Effects reverse upon discontinuation; lifelong therapy typically required 4
6. Cancer screening: Does not prevent prostate cancer; may increase high-grade cancer detection (unclear if causal) 1

Clinical Pearls & Pitfalls

Efficacy Predictors

• Prostate volume: Larger glands (>30cc) respond better; volume predicts treatment outcome 2
• PSA threshold: PSA >1.5 ng/mL necessary for reliable response 2
• Disease progression: Reduces acute urinary retention risk and surgical need in appropriately selected patients 9, 2

Common Pitfalls

1. Forgetting PSA adjustment: Always double measured PSA in men on finasteride for cancer screening—applies to both 1 mg and 5 mg doses 2, 3
2. Premature discontinuation: Counsel on slow onset to prevent early abandonment of effective therapy 2
3. Inadequate patient selection: Using in small prostates (<30cc) or low PSA (<1.5 ng/mL) yields poor results 2
4. Intraoperative floppy iris: Document finasteride use for patients undergoing cataract surgery (though this is primarily an alpha-blocker concern) 9

Combination Therapy Considerations

• Combining with alpha-blockers increases adverse effects (particularly sexual dysfunction, dizziness, postural hypotension) but may improve efficacy for BPH progression 1
• No new adverse events unique to combination therapy; effects are additive 1